Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
- Aricept Label Now Modified for Lewy Body Dementia Indication: Eisai
November 30, 2022
- Shionogi Curbs Shipments of Xofluza 10 mg on Big Demand
November 30, 2022
- Parexel Poised to Upsize Japan Workforce by 10%-Plus as Opportunities Expand
November 30, 2022
- SanBio Links Arms with Keio University on Alzheimer’s Drug Research
November 30, 2022
- No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
- Kyowa Kirin Unit, Grunenthal Seal JV Deal for Established Medicines Biz
November 28, 2022
- Mediator Sees Potential for Turnaround in Nichi-Iko’s Restructuring Plan
November 28, 2022
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
- Opdivo Secures Top-Selling Title, Veklury Runner Up in July-September: IQVIA
November 25, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- AbbVie Japan Launches Maviret for Age 3 and Older
November 25, 2022
- Takeda’s Dengue Vaccine Bags Fast-Track Tag in US
November 25, 2022
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
- Chugai to Transfer Bonviva Marketing Rights to Taisho
November 25, 2022
- FunPep’s Functional Peptide Fails in Japan PIII Study for Skin Ulcers
November 25, 2022
- Mitsubishi Tanabe, Sumitomo in Antibiotics Collabs with GARDP
November 25, 2022
- Eisai, Shimadzu Kick Off Blood Biomarker Research ahead of Lecanemab Launch
November 24, 2022
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…